NCT01691313View on ClinicalTrials.gov

Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

October 31, 2013

Conditions
Symptomatic Atrial FibrillationAtrial Flutter
Interventions
DRUG

Vanoxerine

single oral dose

DRUG

Placebo

single oral dose

Trial Locations (6)

Unknown

Ashkelon

Haifa

Nazareth

Safed

Moscow

Saint Petersburg

Sponsors
All Listed Sponsors
lead

Laguna Pharmaceuticals, Inc.

INDUSTRY